Imagine your immune system is a security team that can't find the hidden intruders in a building. This technology acts like a loud alarm that wakes up the security team and tells them exactly where the intruders are, even in far-off rooms. Unlike previous alarms that had to be placed manually inside each room, this one is delivered through a simple IV drip to cover the whole body.
Current TLR4 agonists are limited to local injections due to toxicity, making them useless for metastatic cancers. This leaves 90% of the market without a viable systemic immune-stimulation option.
ONCO-Boost, a first-in-class intravenous TLR4 immune modulator. It includes an industrializable manufacturing process and a path toward phase 1/2 clinical trials.
If you are a pharmaceutical company dealing with the low efficacy of current immunotherapies in 'cold' tumors — this project developed ONCO-Boost that transforms these tumors into 'hot' ones. This allows for combination therapies that can target metastatic patients, representing 90% of the market.
If you are a biotech firm dealing with the limitation of local-only injections for TLR4 agonists — this project developed a safe intravenous delivery system. This expands the treatable patient base by 10x compared to competitors limited to intratumoral injection.
If you are a CRO dealing with the need for new clinical trial candidates for osteosarcoma — this project developed a first-in-class immunostimulant. It is moving toward phase 1/2 clinical trials to validate safety and efficacy.
Based on available project data, specific pricing or cost per dose is not disclosed.
Yes, one of the three key value milestones of the project is the industrialization of the manufacturing process to supply the market with large quantities of drugs.
Based on available project data, the technology was developed by HEPHAISTOS-PHARMA, but specific patent numbers or licensing terms are not listed.
The project is specifically targeting regulatory validation through the acquisition of a Clinical Trial Authorization (CTA).
The project runs from 2024-05-01 to 2026-02-28, with the goal of becoming a clinical stage company by 2026.
The project is led by a single French SME, HEPHAISTOS-PHARMA, which maintains 100% industry control. This lean structure suggests a fast-track approach to commercialization, focusing on internal development rather than academic partnerships.
Contact HEPHAISTOS-PHARMA in France
Contact us to explore licensing opportunities for ONCO-Boost.
